Minoxidil and caffeine are discussed for hair loss treatment. The user questions the logic of combining them due to their opposing effects on adenosine receptors.
A 22-year-old male with hair loss is considering treatments like finasteride, minoxidil, and derma rolling after being diagnosed with MPB, vitamin D deficiency, and dandruff. He seeks advice on whether these treatments can realistically improve his hair density and achieve a healthier NW2.
A 29-year-old man shared his 4-month hair regrowth progress using Dutasteride and Ketoconazole shampoo. The conversation focuses on these specific hair loss treatments.
A user experimented with creatine while using finasteride and minoxidil for hair loss, noticing increased bald spots and thinner hair, but attributed it to his hair cycle rather than creatine. Other users suggested that creatine doesn't cause hair loss directly, but increased testosterone from workouts might affect those with a genetic predisposition.
A user shared their 4-year hair loss journey, starting with finasteride and minoxidil, then adding dutasteride and oral minoxidil, which improved their hair. They are now considering RU58841 and a hair transplant in the future.
The user experienced good hair growth using topical minoxidil 5% and finasteride for 4 months but lost progress after switching to oral minoxidil and finasteride and shaving their head. They have returned to using topical treatments and are seeking advice on similar experiences.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
The conversation is about hair loss and the conclusion is that genetics play a significant role in hair loss, and lifestyle choices or being a well-adjusted person do not prevent male pattern baldness.
The user reported significant hair thickness improvement using Minoxidil 5% twice daily for three months and Finasteride 1mg daily for one month, along with Biotin and Vitamin D supplements. The user no longer notices bald patches and is hopeful for continued progress.
Hair loss progress in 4.5 months using dutasteride 3x/week, topical minoxidil 1-2x daily, and microneedling 2x/month. Users praised the significant improvement.
PP405 may revive dormant hair follicles, and DHT blockers like finasteride or dutasteride could maintain new hair. Combining PP405 with minoxidil might be optimal, but long-term effects and continuous use are uncertain.
A 27-year-old using minoxidil and dutasteride for hair loss has seen significant improvement but is considering a hair transplant for a more defined hairline. Most responses suggest the hair looks good, advise against a transplant, and recommend patience or trying microneedling or tretinoin.
GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.
Kintor Pharma announced successful Phase II trial results for KX-826 in treating hair loss, showing it's comparable to finasteride and can be used with it. Some participants saw a 10 hair/cm^2 increase, which is considered a good outcome at the low dose used.
The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. It also inquires about the timeline for the GT20029 phase 3 trial by Kintor.
The conversation discusses a patent filed by Shiseido for cloning Dermal Papilla (DP) cells to treat hair loss. The method involves using viral vectors to maintain the cells' growth-inducing properties, differing from Replicel's approach with Dermal Sheath Cup (DSC) cells.
The user experienced significant hair regrowth using 5 mg daily oral minoxidil and ketoconazole shampoo, improving from Norwood 3 to Norwood 2. They recommend starting treatment early, noting reduced shedding and stable results.
The conversation discusses the potential benefits of topical caffeine for Androgenetic Alopecia (APA) and female pattern hair loss. While some studies suggest positive results, there's no reliable scientific evidence to strongly recommend caffeine compounds for hair regrowth.
The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
Adding caffeine to topical minoxidil is unlikely to enhance its effectiveness, with most users agreeing it has minimal impact. The main treatments discussed are minoxidil and finasteride, with some users adding other ingredients like azelaic acid and retinol.
People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.
A 24-year-old experienced hair regrowth with finasteride, minoxidil, and ketoconazole but saw a significant shed after four years despite continued treatment and healthy habits. They stopped minoxidil after shaving their head, noticed dandruff disappeared, and are seeking advice for potential regrowth.
New hair loss treatments like GT20029 and PP405 could potentially replace minoxidil and finasteride, offering better results with fewer side effects. However, current treatments like finasteride and minoxidil are still effective for many, despite concerns about side effects.
The post discusses a user's hair loss treatment involving Dutasteride 2.5 mg 5 times per week, Finasteride 1mg 4 times per week, RU58841 daily, and Minoxidil twice daily. A reply suggests that the combination is excessive, particularly the use of both Dutasteride and Finasteride, and labels it as a "chemical castration protocol".
The conversation discusses the results of a group buy for Ky19382 related to hair loss treatments. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
KX-826, Breezula, PP405, and Stemson are potential future treatments for hair loss, with varying timelines and mechanisms like blocking DHT and stem cell activation. Users express skepticism about the timeline and mention current options like hair transplants and minoxidil.
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.